← Back to Search

Phosphodiesterase inhibitor

Ibudilast for COVID-19

Phase 2
Waitlist Available
Research Sponsored by MediciNova
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 7, 14, 28 and 60 (day 60 applies to intubated subjects only)
Awards & highlights

Study Summary

This trial is testing whether a drug called MN-166 can help people with COVID-19 who are at risk of developing acute respiratory distress syndrome.

Eligible Conditions
  • Viral Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 7, 14, 28 and 60 (day 60 applies to intubated subjects only)
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 7, 14, 28 and 60 (day 60 applies to intubated subjects only) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects free from respiratory failure at Day 7
Proportion of subjects with at least a 1-point improvement in clinical status using the National Institute on Allergy and Infectious Disease 8-point ordinal scale and discharge record at Day 7
Secondary outcome measures
Adverse event incidence and severity
All-cause mortality at Days 7,14, 28, and 60
Incidence of mechanical ventilation or intubation at Day 7, 14, 28, and 60
+4 more

Side effects data

From 2017 Phase 2 trial • 125 Patients • NCT01860807
50%
Headache
17%
Nausea
16%
Insomnia
13%
Diarrhea
2%
Suicide Attempt
2%
Convulsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ibudilast
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MN-166 (ibudilast)Experimental Treatment1 Intervention
MN-166 capsules, 50 mg twice daily, for 7 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsules, 50 mg twice daily, for 7 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibudilast
2013
Completed Phase 2
~340

Find a Location

Who is running the clinical trial?

MediciNovaLead Sponsor
19 Previous Clinical Trials
1,480 Total Patients Enrolled
Kazuko Matsuda, MD PhD MPHStudy ChairMedicinova Inc
4 Previous Clinical Trials
339 Total Patients Enrolled

Media Library

Ibudilast (Phosphodiesterase inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04429555 — Phase 2
Viral Pneumonia Research Study Groups: Placebo, MN-166 (ibudilast)
Viral Pneumonia Clinical Trial 2023: Ibudilast Highlights & Side Effects. Trial Name: NCT04429555 — Phase 2
Ibudilast (Phosphodiesterase inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04429555 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS
2021. "Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04429555.
All > Covid
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top